Rhonda Farnum insider trades: Theravance Biopharma (TBPH) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Rhonda reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TBPH | ↓ Sell | 13,314 | $17.03 | $227K | Direct | Sep 17, 2026 (2d) |
| Jun 15, 2026 | TBPH | ↓ Sell | 13,314 | $16.39 | $218K | Direct | Jun 17, 2026 (2d) |
| Mar 16, 2026 | TBPH | ↓ Sell | 31,067 | $13.96 | $434K | Direct | Mar 18, 2026 (2d) |
| Dec 3, 2025 | TBPH | ↓ Sell | 31,067 | $18.75 | $583K | Direct | Dec 5, 2025 (2d) |
| Jul 14, 2025 | TBPH | ↓ Sell | 10,000 | $11.39 | $114K | Direct | Jul 16, 2025 (2d) |
| Jun 2, 2025 | TBPH | ↓ Sell | 24,000 | $11.00 | $264K | Direct | Jun 4, 2025 (2d) |
| Apr 21, 2025 | TBPH | ↓ Sell | 4,000 | $9.00 | $36K | Direct | Apr 23, 2025 (2d) |
| Jan 21, 2025 | TBPH | ↓ Sell | 4,000 | $9.00 | $36K | Direct | Jan 23, 2025 (2d) |
| Nov 11, 2024 | TBPH | ↓ Sell | 4,000 | $9.00 | $36K | Direct | Nov 13, 2024 (2d) |
| Jul 10, 2024 | TBPH | ↓ Sell10b5-1 | 4,000 | $9.00 | $36K | Direct | Jul 12, 2024 (2d) |
| Feb 22, 2024 | TBPH | ↓ Sell10b5-1 | 1,254 | $8.71 | $11K | Direct | Feb 22, 2024 (0d) |
| Nov 21, 2023 | TBPH | ↓ Sell10b5-1 | 1,378 | $10.29 | $14K | Direct | Nov 22, 2023 (1d) |
| Aug 22, 2023 | TBPH | ↓ Sell10b5-1 | 1,807 | $9.47 | $17K | Direct | Aug 24, 2023 (2d) |
| Jun 8, 2023 | TBPH | ↓ Sell10b5-1 | 1,790 | $11.13 | $20K | Direct | Jun 12, 2023 (4d) |
| Mar 9, 2023 | TBPH | ↓ Sell | 4,000 | $10.20 | $41K | Direct | Mar 13, 2023 (4d) |
| May 23, 2022 | TBPH | ↓ Sell10b5-1 | 1,081 | $8.93 | $10K | Direct | May 24, 2022 (1d) |
| Feb 28, 2022 | TBPH | ↓ Sell10b5-1 | 2,356 | $10.16 | $24K | Direct | Mar 2, 2022 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TBPH insiders
Open-market trades in the last 12 months
About Rhonda Farnum's insider trades
Rhonda Farnum is SVP, Comm & Medical Affairs at Theravance Biopharma (TBPH). Since Feb 28, 2022, Rhonda has reported no open-market purchases and 17 sales worth $2.1M on SEC Form 4. In the last 12 months: 4 sales ($1.5M).
7 sales (6% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include shares withheld for taxes (19 filings), grants and awards (6 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TBPH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.